Soc. Generale Knock-Out ABBV/ DE000CJ5P0T9 /
07/06/2024 21:51:17 | Chg.+0.180 | Bid21:58:24 | Ask21:58:24 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
11.950EUR | +1.53% | 11.950 Bid Size: 4,000 |
11.960 Ask Size: 4,000 |
AbbVie Inc | 41.4228 USD | 31/12/2078 | Call |
GlobeNewswire
05/06
CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...
GlobeNewswire
05/06
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
04/06
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
03/06
ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...
GlobeNewswire
01/06
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...
GlobeNewswire
28/05
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...
GlobeNewswire
28/05
CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...
GlobeNewswire
28/05
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
GlobeNewswire
25/05
CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...
GlobeNewswire
24/05
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...
GlobeNewswire
23/05
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
22/05
Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...
GlobeNewswire
22/05
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
22/05
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
22/05
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...